Tesamorelin

Growth hormone-releasing factor analog

Tesamorelin is different from many performance peptides because it has an approved prescription context for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. PeptideStack keeps that indication clear.

EgriftaEgrifta SV

What It Is

Mechanism: Tesamorelin stimulates growth hormone release through growth hormone-releasing factor activity.

Research Areas

HIV-associated lipodystrophy context

Human clinical evidence

Months in trials

Body-composition tracking

Indication-specific

Months

GH-axis safety context

Clinically relevant

Ongoing

Evidence Context

Top labels, trials, papers, and regulatory sources tied to Tesamorelin. This is research context, not treatment advice.

1 sources

Source2024

DailyMed EGRIFTA SV prescribing information

Official labeling context helps keep tesamorelin tied to its specific approved indication and monitoring boundaries.

Approved indication contextPrescribing informationdailymed-tesamorelin

What to track first

Because tesamorelin has a specific approved context, tracking should emphasize indication, labs, clinician direction, glucose context, edema, and body-composition measures.

• Track prescribed indication, waist or imaging context, labs, glucose notes, edema, and side effects.

• Keep HIV-associated lipodystrophy context distinct from general weight-loss or bodybuilding claims.

• Use clinician-directed care as the source of the plan.

Injection-site reactions

Clinically recognizedMild to variable

Track route, site, and timing.

Swelling or fluid retention

Clinically recognizedVariable

Track edema and weight changes.

Glucose changes

Clinically relevantHigh context need

Track labs and clinician guidance.

Research Status

Prescription medication for a specific HIV-associated lipodystrophy indication.

Stack Context

Approved-indication context

Track the indication, clinician plan, labs, waist measures, and side effects.

GH-axis context

Track edema, glucose, sleep, and recovery without overextending claims.

Warnings

• Tesamorelin is not a generic weight-loss peptide.

• Cancer, pituitary disease, pregnancy, and glucose concerns require clinician oversight.

• Follow approved labeling and clinician direction for the indicated use.

Start Tracking

Track tesamorelin with indication context, labs, body-composition measures, edema, and clinician-directed notes.

Tesamorelin strengthens PeptideStack credibility when it is framed by its specific approved indication and monitoring needs.

Open App Funnel View Tools